Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.

JCO precision oncology - 1 Sept 2023

Ernst Sophie M, Uzun Sevim, Paats Marthe S, van Marion Ronald, Atmodimedjo Peggy N, de Jonge Evert, van Schaik Ron H N, Aerts Joachim G J V, von der Thüsen Jan H, Dubbink Hendrikus J, Dingemans Anne-Marie C

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Open in PubMed Open full text

Identifiers

PMID: 38096473
DOI: 10.1200/PO.23.00451
PMCID: PMC10735074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases.PMID 38096473Read ↗

Patients with uncommon EGFR mutations also benefit from first-line osimertinib.Semantic proximity Read ↗

Mechanisms of osimertinib resistance and emerging treatment options.Semantic proximity Read ↗

A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib.Semantic proximity Read ↗

Low-Dosage Apatinib in Treating Advanced Pulmonary Adenocarcinoma With Kras Mutation After Osimertinib Resistance: A Case Report.Semantic proximity Read ↗

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the LiteratureSemantic proximity Read ↗

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroSemantic proximity Read ↗

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.Semantic proximity Read ↗

Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.Semantic proximity Read ↗

Two Driver Mutations Exist in Osimertinib-Resistant Patient Tumors.Semantic proximity Read ↗

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.Semantic proximity Read ↗

Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations.Semantic proximity Read ↗

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.